Startups

We take pride in supporting our team members in their entrepreneurial endeavors and startups. This was acknowledged by the ETH Zurich Dandelion Entrepreneurship Award and Special Award for championing interdisciplinary collaboration and entrepreneurship in 2022.
We would like to thank all ETH students, PhDs, and Post-Docs who nominated Professors for the award and helped recognize the most entrepreneurial friendly Professors at ETH Zurich! Based on the nominations, a jury picked a winner for each department. The jury consisted of representatives of relevant ETH institutions, such as ETH Entrepreneur Club, ETH juniors, Student Project House, and AVETH.

external page https://www.dandelion-award.com/winners-2022

catchfree AG

We are Sevi & Eddy, the co-founders of catchfree. Together, we deliver consumers a plant-only alternative to their favourite seafood. At catchfree, we create tasty plant-only seafood that delights your taste buds and the planet.

Our healthy and savory seafood is flipping the script on the harmful impact of traditional seafood production. Made from natural ingredients only, we’re crafting plant-only seafood without harming nature.

external page https://www.catchfree.ch

IMAI MedTech GmbH

The beginning of IMAI can be traced back to Francesca Catto's collaboration during her Ph.D. at the Aguzzi Laboratory with Stephan Fox, a product development and mechanical engineering specialist at ETH. Their innovative efforts were later strengthened by Robert Axelrod during his PhD at the Mathys lab, and by Sascha Brun, who joined the project during his master's studies under Fox's guidance. Officially founded in 2024 by Robert, Francesca, and Sascha, IMAI welcomed Martina and Beda to the team, furthering its mission to revolutionize cancer diagnostics through the application of 3D histology.

IMAI is on a mission to redefine the landscape of oncology diagnostics through its pioneering 3D histology technology. By focusing on the early and accurate diagnosis of cancer, IMAI aims to enhance therapeutic outcomes and significantly improve patient care.

Envisioning a future in which its cutting-edge histology technology becomes a cornerstone of clinical practice, IMAI is committed to transforming the approach to cancer diagnosis. This vision includes early stage diagnosis and a deeper understanding of cancer mechanisms, which will lead to optimized treatment plans and better outcomes for patients worldwide.  

external page https://www.imai-medtech.com